OPB-201
/ Outpace Bio
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
June 25, 2026
A Phase 1 Study to Evaluate the Safety and Efficacy of OPB-201 in Recurrent Endometrial and Platinum-resistant Ovarian Cancer.
(clinicaltrials.gov)
- P1 | N=30 | Not yet recruiting | Sponsor: Outpace Bio, Inc.
New P1 trial • Platinum resistant • Endometrial Cancer • Melanoma • Oncology • Ovarian Cancer • Solid Tumor • BRCA1 • BRCA2 • PRAME
1 to 1
Of
1
Go to page
1